For many years respiratory syncytial virus was seen as a seasonal inconvenience – a mild cold for children and a nagging cough for adults. In older populations, however, the same virus can lead to hospitalization, intensive‑care admission and death.
Global estimates have long shown about 64 million infections each year and roughly 160,000 fatalities, yet no vaccine existed to curb the toll. The landscape shifted in 2023 when GSK’s Arexvy became the first RSV vaccine to receive regulatory approval anywhere in the world, cleared by the U.S. Food and Drug Administration for adults aged 60 and older. Pfizer’s Abrysvo followed a short time later, and in 2024 Moderna’s Mresvia joined the list.
All three products are directed at the same age group that faces the highest risk of severe outcomes. After reviewing the accumulated data, the U.S. Centers for Disease Control and Prevention waited until mid‑June 2024 to issue updated advice.
Released on June 15, the guidance does not call for universal vaccination among seniors. Instead it adopts a focused approach. Individuals who are 75 years of age or older and have never received an RSV vaccine are advised to get one.
For adults between 60 and 74, the recommendation is limited to those with conditions that increase the danger of a severe respiratory infection – such as chronic lung disease, heart disease or other ailments that compromise respiratory health. The CDC emphasizes that it is not treating all older adults the same; the line drawn is based on assessed risk rather than age alone.
The rationale rests on well‑known age‑related changes. Immune function wanes with advancing years, lungs lose elasticity, and existing chronic conditions can amplify the damage caused by a respiratory virus. In a healthy adult RSV typically produces a week of congestion and fatigue, but in an 80‑year‑old with heart failure the same infection can precipitate pneumonia. Vaccination aims to interrupt that progression.
Arexvy has already secured expanded use in the United States for people aged 50 to 59 who are at heightened risk. The same vaccine is also authorized in the European Union and Canada for adults 60 and older.
While the exact approvals differ by region, the overarching pattern is consistent: regulators view the shots as safe and effective and intend them for those most likely to benefit. Clinical trials for all three candidates demonstrated strong protection against severe disease, a finding that convinced authorities to grant licensure. Real‑world effectiveness will continue to be monitored; the CDC plans to track hospitalizations and breakthrough infections during the upcoming RSV season and adjust recommendations if warranted – a standard step for any newly introduced vaccine.
Timing matters because RSV typically circulates from fall through spring in the Northern Hemisphere. By publishing the guidance in June, the agency gives clinicians, pharmacies and public‑health officials several months to prepare before the virus begins to spread again.
Vaccines will be stocked at retail pharmacies, offered in primary‑care settings, and promoted through outreach aimed at the oldest and most vulnerable Americans.
